{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Nodal response rate was to be assessed by an IRC.","groups":[{"description":"Idelalisib (Zydelig®) 150 mg tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 6 total cycles) + rituximab (375 mg/m\\^2 on Day 1 and 500 mg/m\\^2 thereafter for at total of 6 infusions)","id":"OG000","title":"Idelalisib+Bendamustine+Rituximab"},{"description":"Placebo tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 6 total cycles) + rituximab intravenously (375 mg/m\\^2 on Day 1 and 500 mg/m\\^2 thereafter for at total of 6 infusions)","id":"OG001","title":"Placebo+Bendamustine+Rituximab"}],"populationDescription":"The study was terminated in agreement with the FDA due to urgent safety measures. Complete data were not collected for any participant.","reportingStatus":"POSTED","timeFrame":"Up to 22 months","title":"Nodal Response Rate","type":"SECONDARY"}